Literature DB >> 10672850

Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels.

X Zhang1, X Xu, A Nasjletti, T H Hintze.   

Abstract

Our previous study found that angiotensin-converting enzyme (ACE) inhibitors and amlodipine induce NO release from coronary microvessels through a kinin-dependent mechanism. The goal of this study was to determine whether amlodipine could potentiate NO formation during ACE inhibition. Coronary microvessels were isolated from 16 mongrel dogs. Nitrite, the hydration product of NO, from coronary microvessels was quantified by using the Griess reaction. Bradykinin and kallikrein all significantly increased nitrite release from coronary microvessels in a concentration-dependent manner. The ACE inhibitor, ramiprilat, potentiated these effects. Amlodipine also markedly potentiated nitrite production by ramiprilat. For instance, amlodipine (10(-10) M) enhanced nitrite release induced by ramiprilat (10(-7) M) from 122 +/- 9 to 168 +/- 14 pmol/mg (p < 0.05 vs. ramiprilat). Nitrite release potentiated by ramiprilat and amlodipine was entirely blocked by N(omega)-nitro-L-arginine methyl ester (L-NAME, an inhibitor of NO synthase), HOE 140 (Icatibant, a specific B2-kinin receptor antagonist), and dichloroisocoumarin (DCIC, a serine protease inhibitor that blocks local kinin formation). These results clearly show that there is a synergistic effect on NO formation when amlodipine is combined with ACE inhibition. Our data suggest that kinin-mediated coronary NO production may contribute importantly to the beneficial therapeutic action of ACE inhibitors, especially in combination with amlodipine in the treatment of heart disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672850     DOI: 10.1097/00005344-200002000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism.

Authors:  Biao Xu; Li Xiao-hong; Gao Lin; Lindsay Queen; Albert Ferro
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 2.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

3.  Preservation of NO production by statins in the treatment of heart failure.

Authors:  Jean-Noel Trochu; Seema Mital; Xiao ping Zhang; Xiaobin Xu; Manuel Ochoa; James K Liao; Fabio A Recchia; Thomas H Hintze
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

4.  Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure.

Authors:  Ehsan Aali; Habib Ghaznavi; Mohammad Soleiman Soltanpour; Massoud Mahmoudian; Massoumeh Shafiei
Journal:  Iran J Med Sci       Date:  2021-03

5.  A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.

Authors:  Emile R Mohler; David Herrington; Pamela Ouyang; Charles Mangano; Susan Ritter; Pamela Davis; Das Purkayastha; Marjorie Gatlin; Robert A Vogel
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

Review 6.  Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker.

Authors:  Brent M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

Review 7.  Systolic hypertension in the elderly: pushing the frontiers of therapy--a suggested new approach.

Authors:  Gordon S Stokes
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

Review 8.  Risk-based classification of hypertension and the role of combination therapy.

Authors:  Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

Review 9.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009

10.  The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).

Authors:  Kenneth A Jamerson
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.